{"uid":"cap_XzSaVVUZgIt2I1Ikewopz","slug":"clinicalintelpulse-clinical-trial-failure-analysis-247be75a","name":"ClinicalIntelPulse Clinical Trial Failure Analysis","description":"Clinical trial failure analysis for a disease area — why Phase 2/3 trials failed (wrong target, patient population, endpoint, dose, safety), failure taxonomy with percentages, phase-transition success rates and design lessons. Worldwide. For drug developers and biotech investors.","url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/failure-analysis","method":"GET","headers":{},"bodySchema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"condition":{"type":"string"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}}}},"responseSchema":{"type":"json","example":{"query_summary":{"condition":"Alzheimer Disease","trials_analyzed":78},"lessons_learned":["Early intervention is critical — treat pre-symptomatic or MCI only","Amyloid PET and CSF biomarkers required for enrollment (not just clinical diagnosis)","CDR-SB global score now accepted primary endpoint by FDA (post-2018)","ARIA management protocols must be pre-specified — not post-hoc","Combination approaches (amyloid + tau + neuroinflammation) likely needed"],"failure_taxonomy":{"wrong_endpoint":{"pct":18,"examples":["ADAS-Cog and MMSE insensitive to early disease changes; CDR-SB now standard"],"key_trials":["Multiple agents 2010-2020"]},"safety_termination":{"pct":8,"examples":["ARIA (amyloid-related imaging abnormalities) from anti-amyloid antibodies; dose-limiting"],"key_trials":["Aducanumab Phase 3 dose arm"]},"operational_failures":{"pct":4,"examples":["COVID-19 disruption, enrollment failures in rare AD subpopulations"]},"wrong_patient_population":{"pct":28,"examples":["Treating symptomatic patients too late — amyloid deposited 10-15 years before symptoms"],"key_trials":["Bapineuzumab (mild-moderate vs. early)"]},"wrong_target_or_hypothesis":{"pct":42,"examples":["Decades of amyloid-only focus; tau, neuroinflammation, synaptic loss all contributing to failure cascade"],"key_trials":["Solanezumab","Verubecestat","Atabecestat"]}},"what_still_might_fail":["Tau-targeting agents if amyloid clearance alone sufficient","Agents tested in wrong disease stage despite lessons","CNS inflammation approaches without biomarker stratification"],"historical_success_rates":{"phase2_to_phase3_pct":31,"phase3_to_approval_pct":11,"vs_all_diseases_benchmark":"Alzheimer's has the lowest Phase 3 success rate of any major disease category (11% vs. 58% oncology, 67% hematology)","overall_clinical_success_pct":3.4},"successful_design_principles":"CLARITY-AD (lecanemab) and TRAILBLAZER-ALZ2 (donanemab) succeeded by: earlier disease staging, biomarker-confirmed enrollment, CDR-SB endpoint, adequate duration."}},"example":null,"exampleRequest":null,"tags":["x402"],"displayCostAmount":"0.2","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"probe","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.2/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.2","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.2","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_7KwRfcDkUz14XkIdSwy91","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.2","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Returns a structured failure taxonomy for Phase 2/3 clinical trials in a disease area, including failure reasons, percentages, phase-transition success rates, and design lessons.","exampleAgentPrompt":"Give me a failure analysis for Phase 2 and Phase 3 oncology trials — break down the taxonomy of why they failed (wrong target, wrong patient population, endpoint selection, dose, safety issues), with percentages and phase-transition success rates plus key design lessons.","exampleUseCases":[{"title":"Alzheimer's drug trial risk assessment","prompt":"We're considering investing in an early-stage Alzheimer's biotech. Can you pull the failure taxonomy for Phase 2 and Phase 3 trials in that space — what percentage fail on endpoints versus patient population mismatches, and what are the phase-transition success rates? I need to understand the biggest risks."},{"title":"NASH trial design optimization before IND","prompt":"Our team is designing a Phase 2 NASH trial and we want to avoid common pitfalls. What does the failure data show — are most NASH trials failing on wrong endpoints, wrong patient populations, or safety signals? And what's the success rate getting from Phase 2 to Phase 3?"},{"title":"Rare disease phase-transition benchmarking","prompt":"We have a rare autoimmune indication and need to benchmark our phase-transition assumptions. What are the historical success rates moving from Phase 2 to Phase 3 in autoimmune diseases, and what are the top three reasons trials fail at each stage? We want to reality-check our go/no-go criteria."}],"resultDescription":"A structured failure taxonomy for Phase 2/3 trials in the queried disease area, including categorized failure reasons (wrong target, patient population mismatch, endpoint failure, dose issues, safety signals), percentage breakdowns across categories, historical phase-transition success rates, and actionable design lessons for drug developers and biotech investors.","failureModes":["Unknown or unsupported disease area returns empty or error response","Overly broad disease category may return low-confidence aggregated data","Rate limiting or payment failure if USDC balance is insufficient","Network timeout for complex or data-sparse disease areas"],"whenToPreferThis":"Use this endpoint when you need structured, quantitative intelligence on why clinical trials fail in a specific disease area — particularly for informing trial design decisions, go/no-go investment assessments, or competitive risk benchmarking. Prefer this over general pipeline endpoints when the core question is root-cause analysis of trial failure rather than active pipeline status or approval probability.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-09-14T06:35:15.478Z","isFirstParty":false}